文献速递炎症性肠病

炎症性肠病患者对SARS-CoV-2疫苗初始体液免疫应答的影响因素

Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases.
PubMed 文献 · Am J Gastroenterol · 2022-01-01

这项前瞻性队列纳入1909例已接种SARS-CoV-2疫苗的炎症性肠病患者,96%产生阳性抗体应答。多因素分析显示,年龄较大、接种BNT162b2 vs mRNA-1273、抗TNF联合6MP/硫唑嘌呤/甲氨蝶呤与缺乏抗体应答相关;5-氨基水杨酸或柳氮磺吡啶及乌司奴单抗与缺乏抗体应答风险降低相关。

要点

  • 1909例炎症性肠病患者中96%对SARS-CoV-2疫苗产生初始阳性抗体应答。
  • 年龄较大、接种BNT162b2 vs mRNA-1273、抗TNF联合免疫调节剂与缺乏抗体应答相关。
  • 5-氨基水杨酸或柳氮磺吡啶及乌司奴单抗与缺乏抗体应答风险降低相关。

核心结论

  • 多数炎症性肠病患者对SARS-CoV-2疫苗产生初始应答,但年龄较大及接受抗TNF联合免疫调节剂治疗者应答减弱,可能最受益于额外疫苗剂量。
  • 接受其他类别免疫抑制药物治疗的患者初始免疫应答较强。

研究设计与样本

  • 前瞻性队列研究,纳入1909例已接种SARS-CoV-2疫苗的炎症性肠病患者。
  • 其中1123例接种BNT162b2、692例接种mRNA-1273、94例接种Ad26.COV2.S。

主要发现

  • 96%的参与者达到阳性抗体应答。
  • 多因素分析中,缺乏抗体应答的相关因素包括年龄较大(P = 0.043)、接种BNT162b2 vs mRNA-1273(OR 2.1,95%CI 1.0-3.9)、抗TNF联合6MP/硫唑嘌呤/甲氨蝶呤(OR 4.2,95%CI 2.4-7.3)。
  • 使用5-氨基水杨酸或柳氮磺吡啶(OR 0.3,95%CI 0.1-0.8)及乌司奴单抗(OR 0.2,95%CI 0.05-0.8)与缺乏抗体应答的 odds 降低相关。

临床怎么用

  • 作者认为,年龄较大及接受抗TNF联合免疫调节剂治疗的患者可能最受益于额外疫苗剂量。
  • 作者认为,这些数据应有助于指导炎症性肠病患者中额外COVID-19疫苗剂量的患者选择决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although an additional coronavirus disease 2019 vaccine dose for immunocompromised persons has been recommended in some countries, further data to guide vaccination strategies for patients with inflammatory bowel disease (IBD) are urgently needed. We sought to identify factors affecting initial humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines among patients with IBD. METHODS: In this prospective cohort of SARS-CoV-2 immunized patients with IBD, we evaluated associations between participant age, sex, vaccine type, medication use, and the presence of a detectable antireceptor binding domain antibody and quantitative antibody level. RESULTS: In total, 1,909 participants were included (1,123, 692, and 94 received BNT162b2, mRNA-1273, and Ad26.COV2.S, respectively) of whom 96% achieved a positive antibody response. On multivariable analysis, factors associated with lack of antibody response were older age (P = 0.043), BNT162b2 vs mRNA-1273 (odds ratio [OR] 2.1, 95% confidence interval [CI] 1.0-3.9), and combination therapy with anti-TNF and 6MP, azathioprine, or methotrexate (OR 4.2, 95% CI 2.4-7.3). The use of 5-aminosalicylate or sulfasalazine (OR 0.3, 95% CI 0.1-0.8) and ustekinumab (OR 0.2, 95% CI 0.05-0.8) was associated with decreased odds of lacking antibody response. DISCUSSION: Most patients with IBD mount an initial response to SARS-CoV-2 vaccination; however, older patients and those treated with anti-TNF and immunomodulator have blunted responses and may benefit the most from an additional vaccine dose. Patients treated with other classes of immunosuppressive medications have more robust initial immune responses to vaccination. These data should inform key decisions about patient selection for additional coronavirus disease 2019 vaccine doses in patients with IBD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kappelman MD, Weaver KN, Zhang X, et al. Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases. Am J Gastroenterol. 2022. PMID: 35029167. doi:10.14309/ajg.0000000000001619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。